NCT02032238终止不适用
Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema
OD-OS GmbH1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2013年3月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Percentage of Eyes That Received Retreatment
研究概览
简要总结
Asses efficacy of navigated laser in reducing the number of anti-VEGF injections as a prospective study using Bevacizumab.
详细描述
The purpose of this is study is to assess the efficacy of navigated laser treatment in reducing the number of anti-VEGF injections required to maintain visual gain obtained after Bevacizumab compared to Bevacizumab alone in patients with clinically significant macular edema (CSME).
This will be prospective, active-controlled study using Bevacizumab (Genentech, South San Francisco CA) for intravitreal injections. Retinal photocoagulation will utilize the Navilas Laser System (OD-OS GmbH, Teltow, Germany), which is an approved indication for this device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
no masking
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CSME and Diagnosis of diabetes mellitus
- •Able and willing to provide informed consent prior to any study-related procedures
- •Central foveal thickness > 250 microns at baseline
- •Best corrected visual acuity between 20/400 and 20/40
- •Willing and able to comply with clinic visits and study-related procedures
- •U.S. patients will be required to have a Health Insurance Portability and Accountability Act (HIPAA) authorization; in other countries, as applicable according to national laws
排除标准
- •- Macular edema is considered to be due to a cause other than diabetic macular edema.
- •An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., macular ischemia, vitreomacular traction, foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).
- •An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.)
- •Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).
- •History of treatment for diabetic macular edema at any time in the past 4 months (such as focal/grid macular photocoagulation, intravitreal or peribulbar corticosteroids, anti-VEGF drugs, or any other treatment).
- •History of panretinal (scatter) photocoagulation (PRP) within 4 months prior to enrollment.
- •History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization. 13
- •History of YAG capsulotomy performed within 2 months prior to randomization.
- •Intraocular pressure >= 25 mmHg.
- •History of open-angle glaucoma (either primary open-angle glaucoma or other cause of open-angle glaucoma; note: history of angle-closure glaucoma is not an exclusion criterion).
- •History of steroid-induced intraocular pressure (IOP) elevation that required IOP-lowering treatment.
- •Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis
- •Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.
- •A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control)
- •Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval at the time of study entry
- •Known allergy to any component of the study drug
- •Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).
- •Major surgery within 28 days prior to randomization or major surgery planned during the next 6 months.
- •Myocardial infarction, other cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization.
- •Systemic anti-vascular growth factor (anti-VEGF) or pro-VEGF treatment within 4 months prior to randomization 14
- •For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months.
- •Subject is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the first 12 months of the study.
研究组 & 干预措施
Bevacizumab, no laser photocoagulation
No Intervention
patients receive Anti-VEGF injections (Bevacizumab) only
laser photocoagulation with bevacizumab
Experimental
Combining laser photocoagulation and Anti-VEGF Injections in a pre-defined manner
干预措施: laser photocoagulation (Device)
结局指标
主要结局
Percentage of Eyes That Received Retreatment
时间窗: 12 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Anti-VEGF treatment associated with laser photocoagulation in patients with macular edema due to branch vein occlusioMacular Edema due to Branch Vein OcclusionACTRN12617001436369Hospital Oftalmológico de Sorocaba15
已完成
不适用
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal NeovascularizationCorneal NeovascularizationNCT00512876Walter Reed Army Medical Center24
已完成
1 期
Intravitreal Bevacizumab and Low Fluence Photodynamic TherapyMyopiaNCT00802126University of Campania "Luigi Vanvitelli"16
终止
2 期
Intravitreal Bevacizumab for Age-Related Macular DegenerationAge Related Macular DegenerationNCT00347165Asociación para Evitar la Ceguera en México50
终止
2 期
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast CancerMetastatic Breast CancerNCT00632541Hoosier Cancer Research Network18